.

Deeper Knowledge, Faster

  • Identify first generic entrants
  • Uncover prior art in expired and abandoned patents
  • Drug patents in 130+ countries

► See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving 500+ biopharmaceutical companies globally:

Covington
Daiichi Sankyo
Chubb
Medtronic
Federal Trade Commission
Colorcon
Chinese Patent Office
Healthtrust
US Department of Justice
Cantor Fitzgerald

Generated: July 27, 2017

DrugPatentWatch Database Preview

RESTASIS Drug Profile

« Back to Dashboard

Which patents cover Restasis, and when can generic versions of Restasis launch?

Restasis is a drug marketed by Allergan and is included in one NDA. There are ten patents protecting this drug.

This drug has one patent family member in one country.

The generic ingredient in RESTASIS is cyclosporine. There are seventeen drug master file entries for this compound. Fourteen suppliers are listed for this compound. Additional details are available on the cyclosporine profile page.

Summary for Tradename: RESTASIS

Patents:6
Applicants:1
NDAs:1
Suppliers / Packagers: see list2
Bulk Api Vendors: see list30
Clinical Trials: see list36
Patent Applications: see list9,716
Formulation / Manufacturing:see details
Drug Prices:see details
DailyMed Link:RESTASIS at DailyMed
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Allergan
RESTASIS
cyclosporine
EMULSION;OPHTHALMIC050790-001Dec 23, 2002RXYesYes► Subscribe► SubscribeY ► Subscribe
Allergan
RESTASIS MULTIDOSE
cyclosporine
EMULSION;OPHTHALMIC050790-002Oct 27, 2016RXYesYes► Subscribe► SubscribeY ► Subscribe
Allergan
RESTASIS
cyclosporine
EMULSION;OPHTHALMIC050790-001Dec 23, 2002RXYesYes► Subscribe► Subscribe ► Subscribe
Allergan
RESTASIS MULTIDOSE
cyclosporine
EMULSION;OPHTHALMIC050790-002Oct 27, 2016RXYesYes► Subscribe► SubscribeY ► Subscribe
Allergan
RESTASIS MULTIDOSE
cyclosporine
EMULSION;OPHTHALMIC050790-002Oct 27, 2016RXYesYes► Subscribe► SubscribeY ► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Expired Patents for Tradename: RESTASIS

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Allergan
RESTASIS
cyclosporine
EMULSION;OPHTHALMIC050790-001Dec 23, 2002► Subscribe► Subscribe
Allergan
RESTASIS
cyclosporine
EMULSION;OPHTHALMIC050790-001Dec 23, 2002► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Non-Orange Book Patents for Tradename: RESTASIS

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
8,618,064Methods of providing therapeutic effects using cyclosporin components► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Tradename: RESTASIS

Country Document Number Estimated Expiration
World Intellectual Property Organization (WIPO)2005032577► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving 500+ biopharmaceutical companies globally:

Deloitte
Covington
US Army
Teva
Cipla
Medtronic
Farmers Insurance
Dow
McKesson
UBS

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted Heap | Mobile and Web Analytics
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot